Key Points
- Elevance Health CFO Mark Kaye sold 10,584 shares at an average price of $440.13, generating approximately $4.66 million and reducing his position by 34.7%.
- The company reported quarterly EPS of $6.99, exceeding estimates by $2.28, while revenue reached $50.44 billion, above analyst expectations.
- Elevance declared a quarterly dividend of $1.72 per share, equivalent to $6.88 annually and a 1.6% yield; analysts maintain a “Moderate Buy” consensus with an average price target of $455.57.
Elevance Health, Inc. (NYSE:ELV - Get Free Report) CFO Mark Kaye sold 10,584 shares of the firm's stock in a transaction that occurred on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the completion of the transaction, the chief financial officer owned 19,919 shares of the company's stock, valued at approximately $8,766,949.47. This trade represents a 34.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Elevance Health Trading Down 1.2%
ELV opened at $440.05 on Friday. Elevance Health, Inc. has a fifty-two week low of $274.84 and a fifty-two week high of $450.69. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.47 and a quick ratio of 1.52. The firm has a market capitalization of $95.43 billion, a price-to-earnings ratio of 18.77, a PEG ratio of 2.32 and a beta of 0.70. The company's 50 day moving average price is $408.32 and its two-hundred day moving average price is $390.89.
Elevance Health (NYSE:ELV - Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.71 by $2.28. The firm had revenue of $50.44 billion during the quarter, compared to analysts' expectations of $49.28 billion. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The company's revenue was up .7% on a year-over-year basis. During the same period in the prior year, the company posted $6.03 EPS. As a group, research analysts predict that Elevance Health, Inc. will post 27.09 earnings per share for the current year.
Elevance Health Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be given a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date is Friday, December 4th. Elevance Health's payout ratio is 29.34%.
Institutional Trading of Elevance Health
Institutional investors have recently bought and sold shares of the company. Citizens Financial Group Inc. RI boosted its position in shares of Elevance Health by 77.0% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 6,604 shares of the company's stock valued at $2,568,000 after purchasing an additional 2,873 shares in the last quarter. Simplicity Wealth LLC increased its holdings in Elevance Health by 1.3% in the third quarter. Simplicity Wealth LLC now owns 1,939 shares of the company's stock worth $754,000 after purchasing an additional 25 shares in the last quarter. Gibbs Wealth Management bought a new stake in Elevance Health in the third quarter worth approximately $209,000. Capital Investment Advisors LLC increased its holdings in Elevance Health by 2.6% in the third quarter. Capital Investment Advisors LLC now owns 1,327 shares of the company's stock worth $516,000 after purchasing an additional 33 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC lifted its stake in Elevance Health by 3.5% in the third quarter. Fifth Third Wealth Advisors LLC now owns 3,953 shares of the company's stock valued at $1,537,000 after buying an additional 135 shares during the period. Institutional investors own 89.24% of the company's stock.
Trending Headlines about Elevance Health
Here are the key news stories impacting Elevance Health this week:
- Positive Sentiment: Third-quarter adjusted earnings per share rose 15.9% and exceeded consensus, while revenue also topped expectations. Elevance raised its 2026 adjusted EPS outlook to at least $29, citing disciplined cost management and improved medical-cost trends. Elevance Health Q3 Results
- Positive Sentiment: Carelon’s expansion and clinical programs remain growth drivers; its cancer program reportedly reduced avoidable inpatient admissions by 15%. Management also highlighted actions intended to improve Medicaid profitability. ELV Q3 Deep Dive
- Positive Sentiment: TD Cowen raised its price target to $495 from $465 and maintained a Buy rating, indicating continued confidence in the earnings recovery. TD Cowen Rating
- Positive Sentiment: Elevance declared a quarterly dividend of $1.72 per share, supporting its shareholder-return profile. Elevance Health Dividend
- Neutral Sentiment: Elevance appointed Jeff Park as president of Carelon in a services leadership shift. The move may support execution, but its financial impact is not yet clear. Carelon Leadership Shift
- Neutral Sentiment: Morgan Stanley lifted its target to $449 from $404 but retained an Equal Weight rating, suggesting limited upside after the recent advance. Morgan Stanley Rating
- Negative Sentiment: Officer Mark B. Kaye disclosed an intent to sell 10,584 shares valued at approximately $4.66 million. While the sale may be routine, it can weigh on sentiment near a 52-week high. Officer Share Sale
- Negative Sentiment: Analysts continue to flag sustainability risks: nine-month operating gain declined, and Medicaid margins remain under pressure. Robert W. Baird kept a Neutral rating with a $406 target, below the current trading level. Elevance Health Earnings Analysis
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on ELV shares. Guggenheim raised their price objective on Elevance Health from $460.00 to $485.00 and gave the stock a "buy" rating in a research report on Thursday. Raymond James Financial set a $450.00 target price on Elevance Health in a report on Tuesday, July 7th. Mizuho set a $490.00 target price on shares of Elevance Health in a research report on Friday. The Goldman Sachs Group reissued a "neutral" rating and set a $451.00 target price on shares of Elevance Health in a research report on Friday. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Elevance Health in a report on Thursday, August 13th. Fifteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $455.57.
Read Our Latest Stock Report on Elevance Health
Elevance Health Company Profile
(
Get Free Report)
Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.
Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
